ACE inhibitors

Auteurs

• Pedro D. Orle ans Juste

Paramètres

• Santé & Médecine
• Milestones in drug therapy

En savoir plus sur le livre

Angiotensin converting enzyme inhibitors (ACEI) are the first antihypertensive agents developed based on a clear understanding of arterial hypertension, a significant cause of morbidity and mortality in both developed and developing countries. CAPTOPRIL, the prototype of the "PRIL" family, faced serious setbacks during clinical development due to alarming reports of side effects in prestigious journals like the New England Journal of Medicine and Lancet, nearly leading to its withdrawal from investigation. However, after careful re-evaluation of patient data and appropriate dose adjustments, CAPTOPRIL proved to be revolutionary in clinical use. This prototype, along with other "PRIL" members, initiated extensive basic and clinical research into ACEI interactions with kinin, endothelin, and nitric oxide systems, as well as the roles of various receptors in their pharmacological actions. This research paved the way for new pharmacological agents, including angiotensin receptor antagonists and, more recently, neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists are also expected to become available to further modulate the pharmacological effects of ACEI.

Achat du livre

• Année de publication: 2001